AVTX: Robust phase IIb HS data and pipeline expansion drive confidence in upcoming phase III and beyond
Strong phase IIb results for abdakibart in HS support phase III advancement, with robust efficacy, favorable safety, and high physician enthusiasm. Expansion plans include a long-acting IL-1 beta antibody and new indications in dermatology and rheumatology, with sufficient capital for key milestone…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.